The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1285
May 5, 2008
View Complete Issue         Table of Contents 2019 
Natalizumab (Tysabri) for Crohn's Disease
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Natalizumab (Tysabri) for Crohn's Disease
May 5, 2008 (Issue: 1285)
Natalizumab (Tysabri - Elan and Biogen) is a monoclonal antibody approved for induction and maintenance treatment of moderate to severe Crohn's disease (CD) refractory to conventional therapies and inhibitors of tumor necrosis factor (TNF). Initially...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Natalizumab (Tysabri) for Crohn's Disease
Article code: 1285b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.